ODR: Issue 001
Friday, July 17, 2026
Industry intelligence for the people who run hormone, peptide, and GLP-1 clinics. One read, then back to work.
5 items and a myth-buster. 6-minute read.
Lead story
FDA staff proposed against all seven peptides, in writing, before the committee has voted CONFIRMED
FDA posted the briefing documents for next week's Pharmacy Compounding Advisory Committee meeting on July 14, a week ahead of the two-business-day floor the beat had been watching for: an introduction and one review per peptide, eight PDFs in total, each review reaching FDA's position independently.
For BPC-157, KPV, TB-500, MOTS-c, Emideltide (also called DSIP), Semax, and Epitalon, in both free-base and acetate forms, FDA's position is written plainly in the introduction: FDA is proposing that each one NOT be included on the 503A bulks list. Each per-substance review arrives there independently, in nearly identical language, that the evaluation criteria weigh against placing the substance on the list. KPV draws the sharpest treatment: FDA flags significant safety concerns and notes it identified no human exposure data for any route of administration (FDA briefing document, KPV, fda.gov, posted 2026-07-14). BPC-157's own review names the same gap for its nominated use: little to no effectiveness evidence for ulcerative colitis, plus the same safety and characterization questions that run through all seven (FDA briefing document, BPC-157, fda.gov, posted 2026-07-14).
The rationale repeats across all seven. Little or no evidence of effectiveness for the nominated uses, not enough safety data, and characterization and immunogenicity questions that ride along with peptides. Every one of these seven nominations was withdrawn by the nominator who filed it. FDA still put all seven in front of the committee.
What this is. A written FDA staff position, handed to an advisory committee, before that committee has met. FDA says as much in the introduction: it does not intend to issue a final determination until the advisory committee process has been considered and the reviews are finalized.
What this is not. Not a vote, not a rule, not a ban. The committee is advisory. It meets July 23 and 24 and votes; the vote is input to FDA, not law. Nothing about any peptide's compounding status changed when these documents posted on July 14. Nothing changes on the day of the vote either. What you can do Monday morning is what you could do last Monday.
Our take. FDA staff rarely publish a unified negative position across every substance in a docket a week ahead of schedule unless the direction is already set internally. Every nominator here pulled their own filing, and FDA still put all seven in front of the committee: that reads as an agency documenting a decision already reached, not a step it forgot. Anyone sourcing these seven on a bet that the committee reverses this position next week is betting on the least likely outcome in the room.
What changed is the information, not the law. Two weeks ago the direction was chatter on the legal beat and we would have printed it as rumor. It is now FDA's own text, pointing the same way for all seven.
Source: FDA staff briefing documents, introduction, fda.gov (posted 2026-07-14)
The Signal
⚖️ Compounding and bulks lists
The docket closes Wednesday. That is FDA's last input before a final call. CONFIRMED
The meeting docket (FDA-2025-N-6895) closes July 22 at 11:59 p.m. Eastern. Read the notice carefully, because it sets two dates and most coverage has collapsed them into one: comments received on or before July 9 were provided to the committee, and comments received after that but by July 22 are taken into consideration by FDA. The committee window shut eight days ago. The FDA window has five days left. If you have real clinical experience with any of the seven, that is the difference between a filing FDA reads before a final determination and no filing at all.
Source: federalregister.gov (published 2026-04-16)The deferred five are expected next. Nothing is on the calendar yet. CONFIRMED
Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF are named for a separate advisory committee meeting that FDA says it will host before the end of February 2027. FDA's own page says the time and location will be scheduled in the coming months, and that a Federal Register notice and docket are still to come. There is no notice and no docket today. Expected, not scheduled. If you stock any of the five, watch for the notice rather than the date.
Source: fda.gov (content current as of 2026-04-15)
💉 GLP-1 enforcement
The 503B GLP-1 comment window closes July 30. CONFIRMED
FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list had its comment period extended on June 26. The deadline is July 30, not the June date a lot of coverage still repeats. Most operators we talk to think this window is shut. It is open for thirteen more days. This one is 503B only, so it speaks to outsourcing-facility supply, not to patient-specific compounding.
Source: federalregister.gov (published 2026-06-26)
🩺 Telehealth and DEA
167 days on the telemedicine clock CONFIRMED
The fourth extension of the COVID-era telemedicine flexibilities runs through December 31, 2026. The permanent special registration rule is still only proposed. If your Schedule III telehealth TRT panel depends on the current flexibility, the contingency work belongs in Q3, not Q4.
Source: federalregister.gov (published 2025-12-31)
Myth-buster: what "off the do-not-compound list" actually bought
Three conflations run through nearly every peptide conversation right now. Each one is wrong in a way that costs money or exposure.
"They came off Category 2, so they are legal now." No, and the reason matters more than the correction. FDA's category-2 page, current as of April 22, 2026, no longer carries the peptides in its active table. They now sit in a separate section headed as substances previously in category 2 that were withdrawn by the nominators. That is the actual mechanism: the people who nominated them pulled the nominations. FDA did not clear them. The agency still records safety language for each one, including for BPC-157, that it has identified no or only limited safety information for the proposed routes and therefore lacks sufficient information to know whether the drug would cause harm. Coming off a list because the paperwork was withdrawn is not permission to compound. CONFIRMED
"The committee votes yes and we are back in business." The committee is advisory. Its vote is a recommendation, not a decision. Getting a substance onto the 503A list still runs through rulemaking after the vote, on a timeline measured in months at best. A yes next week starts a process. It does not end one.
"503A and 503B are close enough." 503A is patient-specific compounding by a pharmacy against a prescription. 503B is an outsourcing facility making batches: separate statutes, separate bulks lists, separate proceedings. The seven peptides in front of the committee next week are a 503A question; the GLP-1 exclusion closing July 30 is 503B. A result on one side says almost nothing about the other.
What changes Monday
If you have clinical-need evidence on the 503B GLP-1 proposal, file it by July 30. The window most operators believe is closed has thirteen days left, and this is the one open docket where an operator filing still reaches FDA at full weight.
If you have real experience with any of the seven peptides, the docket closes Wednesday at 11:59 p.m. Eastern. It will not reach the committee, the July 9 cutoff for that has passed, but FDA takes it into consideration before a final determination. Five days.
Do not re-sequence your sourcing around next week's vote. Nothing about compounding status moves on July 23 or 24. Anyone selling you urgency that week is selling you something. Read the vote as information about the direction of travel, then plan on the rulemaking timeline, not the news cycle.
Put December 31, 2026 on the wall. That is the DEA telemedicine date. If the Schedule III panel matters to your revenue, start the contingency now.
Watch for a Federal Register notice on the deferred five, not for a date. The February 2027 window is FDA's own language, but there is no notice and no docket yet. The notice is the thing that makes it real.
Forward this to an operator who needs it.
Filed by the ODR desk. Corrections: [email protected]. Fixes run at the top of the next issue, never buried. How we source and correct: go.optimized.news
ODR is industry intelligence, not legal or medical advice. Decisions about your practice belong with your counsel and your medical director.
Certainty tags: CONFIRMED cites a primary document, linked at the claim. REPORTED is credible secondary coverage, no primary document in hand. RUMORED is unconfirmed chatter, a lead and not a fact.